---
title: "Integrating TB Treatment into Community Pharmacies in Uganda: Human-Centered Design–Derived Implem"
id: "medrxiv-6-implementation-strategies-for-integrating-tb-treatment-into-community"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-implementation-strategies-for-integrating-tb-treatment-into-community"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1?rss=1"
published_at: "2026-09-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Integrating TB Treatment into Community Pharmacies in Uganda: Human-Centered Design–Derived Implem
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-implementation-strategies-for-integrating-tb-treatment-into-community
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1?rss=1)
- **Published At:** 2026-09-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study used a **Human-Centered Design (HCD)** approach to develop an implementation strategy for integrating **TB treatment** refills into community pharmacies for people with **TB/HIV** in Kampala, Uganda. - Researchers completed the inspiration and ideation phases of HCD: qualitative data collection, observations at community pharmacies, translation of findings into insight statements and How Might We (HMW) questions, and co-design workshops. - Participants included people with TB/HIV, TB and HIV focal persons, Ministry of Health DSD model experts, and pharmacy healthcare providers. - From 26 low-fidelity prototypes, four core implementation strategy components emerged: (1) raising awareness and building trust in pharmacy TB medication refills, emphasizing **privacy**, convenience, and legitimacy; (2) standardizing refill workflows by synchronizing ART and TB refills, creating standard operating procedures, and visual workflow diagrams; (3) strengthening pharmacy capacity via certification, accreditation, and targeted TB training; and (4) enhancing monitoring and quality assurance with SOP manuals and standardized side-effect monitoring checklists. - Low-fidelity prototypes were refined via brainstorming, co-design, and ranked scoring; high-fidelity prototypes were assessed for usability using the System Usability Scale. - The study reports that the adapted strategy and high-fidelity prototypes will be evaluated in a pilot randomized trial to assess effectiveness and implementation for integrating TB treatment into pharmacies in Kampala. - Ethical approvals were obtained from the Makerere University Infectious Diseases Institute Research Ethics Committee and the Uganda National Council for Science and Technology; administrative clearance was provided by Kampala Capital City Authority. All participants gave informed consent. - The authors declared no competing interests. Details on pilot trial design or evaluation outcomes were not reported in this source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=uN8pFZ4yktsI31LhUhlKPDlGth2U6qovWK.qIhClZ34-1789662575.99654-1.2.1.1-0lTAnvLpJ0Vi.efSH_YYYSzhRFfh4HrK0.nCabIhOVjJs.thBAUl0VntUSuc69AO) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Implementation strategies for integrating TB treatment into community pharmacies for people with TB/HIV in Uganda using human-centered design methodology [ View ORCID Profile](http://orcid.org/0000-0001-9065-0389)Jonathan Izudi, Adithya Cattamanchi, Christine Sekaggya-Wiltshire, Rachel King, Noah Kiwanuka, Amanda Sammann doi: https://doi.org/10.64898/2026.09.14.26363070 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Jonathan Izudi 1 Mbarara University of Science and Technology; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jonathan%2BIzudi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Izudi%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJonathan%2BIzudi%2B) * [ORCID record for Jonathan Izudi](http://orcid.org/0000-0001-9065-0389 "Open in new tab") * For correspondence: jonahzd@gmail.com Adithya Cattamanchi 2 UCI: University of California Irvine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Adithya%2BCattamanchi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Cattamanchi%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAdithya%2BCattamanchi%2B) Christine Sekaggya-Wiltshire 3 IDI: Makerere University Infectious Diseases Institute; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christine%2BSekaggya-Wiltshire%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sekaggya-Wiltshire%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChristine%2BSekaggya-Wiltshire%2B) Rachel King 4 UCSF: University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rachel%2BKing%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=King%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARachel%2BKing%2B) Noah Kiwanuka 5 Makerere University CHS: Makerere University College of Health Sciences * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Noah%2BKiwanuka%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kiwanuka%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANoah%2BKiwanuka%2B) Amanda Sammann 4 UCSF: University of California San Francisco; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amanda%2BSammann%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sammann%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmanda%2BSammann%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1301927/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1301927/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1301927/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1301927/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1301927/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background Community pharmacies (private retail drug shops/pharmacies) have emerged as a novel differentiated service delivery (DSD) model for delivering antiretroviral therapy (ART) to people with human immunodeficiency virus (HIV) and could support integrated tuberculosis (TB) medication refills. Using a Human-Centered Design (HCD) methodology, we developed an implementation strategy for integrating TB treatment into pharmacies targeting people with TB/HIV in Kampala, Uganda. Methods We implemented the inspiration and ideation phases of the HCD methodology. During the inspiration phase, we identified themes describing barriers and facilitators to integrating TB treatment into community pharmacies and conducted observations at community pharmacies to understand the care pathway of people with TB/HIV. We translated these qualitative findings into insight statements, design opportunities, and How Might We (HMW) questions. During the ideation phase, we conducted brainstorming and co-design workshops to generate and refine solutions, tested low-fidelity prototypes using ranked scores, and assessed the usability of high-fidelity prototypes using the System Usability Scale. Participants included people with TB/HIV, TB focal persons, HIV focal persons, Ministry of Health DSD model experts, and pharmacy healthcare providers. Results Of 26 low-fidelity prototypes, four implementation strategy components emerged: (1) raising awareness and building trust in pharmacy TB medication refills by TB and HIV focal persons, with a focus on privacy, convenience, and legitimacy; (2) standardizing TB medication refill workflows using synchronized ART/TB refill workflows, standardard operating procedures, and visual diagrams illustrating integration of TB treatment into community pharmacies; (3) strengthening the capacity of community pharmacies through certification, accreditation, and targeted TB training; and (4) strengthening monitoring and quality assurance through standard operating procedure manuals and standardized side-effect monitoring checklists. Conclusion The adapted strategy and high-fidelity prototypes will be evaluated in a pilot randomized trial assessing the effectiveness and implementation of TB treatment integration into pharmacies for people with TB/HIV in Kampala, Uganda. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Protocols ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Makerere University Infectious Diseases Institute Research Ethics Committee (reference number: IDI-REC-2024-98) and the Uganda National Council for Science and Technology (reference number: S4397ES) gave ethical approval. The Directorate of Public and Environmental Health, Kampala Capital City Authority, provided administrative clearance for the study (reference number: DPHE/KCCA/1301/01). All participants gave informed consent either in writing or by thumbprint after receiving comprehensive information about the study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All relevant data are within the manuscript and its Supporting Information files Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.11.26362867v1 "Rare copy number variation in Post-traumatic stress disorder using whole genome sequencing and biobank data")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.11.26362754v1 "Clinical and mechanistic responses to a music-based intervention for pain in adults with irritable bowel syndrome: Protocol for a single-arm pilot study") Posted September 17, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/17/2026.09.14.26363070.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.14.26363070v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/17/2026.09.14.26363070.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Implementation strategies for integrating TB treatment into community pharmacies for people with TB/HIV in Uganda using human-centered design methodology Jonathan Izudi, Adithya Cattamanchi, Christine Sekaggya-Wiltshire, Rachel King, Noah Kiwanuka, Amanda Sammann medRxiv 2026.09.14.26363070; doi: https://doi.org/10.64898/2026.09.14.26363070 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.14.26363070v1%26text%3DImplementation%2520strategies%2520for%2520integrating%2520TB%2520treatment%2520into%2520community%2520pharmacies%2520for%2520people%2520with%2520TB%2FHIV%2520in%2520Uganda%2520using%2520human-centered%2520design%2520methodology "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.14.26363070v1%26t%3DImplementation%2520strategies%2520for%2520integrating%2520TB%2520treatment%2520into%2520community%2520pharmacies%2520for%2520people%2520with%2520TB%2FHIV%2520in%2520Uganda%2520using%2520human-centered%2520design%2520methodology "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.14.26363070v1%26title%3DImplementation%2520strategies%2520for%2520integrating%2520TB%2520treatment%2520into%2520community%2520pharmacies%2520for%2520people%2520with%2520TB%2FHIV%2520in%2520Uganda%2520using%2520human-centered%2520design%2520methodology%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.14.26363070v1%26title%3DImplementation%2520strategies%2520for%2520integrating%2520TB%2520treatment%2520into%2520community%2520pharmacies%2520for%2520people%2520with%2520TB%2FHIV%2520in%2520Uganda%2520using%2520human-centered%2520design%2520methodology "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.14.26363070) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.14.26363070v1&count=horizontal&via=&text=Implementation%20strategies%20for%20integrating%20TB%20treatment%20into%20community%20pharmacies%20for%20people%20with%20TB/HIV%20in%20Uganda%20using%20human-centered%20design%20methodology&counturl=www.medrxiv.org/content/10.64898/2026.09.14.26363070v1 "Tweet This") ## Subject Area * [Public and Global Health ](https://www.medrxiv.org/collection/public-and-global-health) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (617) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (902) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (334) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4820) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (479) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (415) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (650) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1631) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15955) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (33) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1203) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7054) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (733) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1065) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5053) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1435) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1769) * [Hematology](https://www.medrxiv.org/collection/hematology) (586) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1346) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16298) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1173) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (669) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (155) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (725) * [Neurology](https://www.medrxiv.org/collection/neurology) (7283) * [Nursing](https://www.medrxiv.org/collection/nursing) (368) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1082) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1241) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1005) * [Oncology](https://www.medrxiv.org/collection/oncology) (3611) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1054) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (398) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (457) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (471) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (709) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1801) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (737) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (767) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5906) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9763) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2429) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1454) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1249) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (642) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (772) * [Sports Medicine](https://www.medrxiv.org/col
## Related Clinical Research

- [Temporal patterns of tuberculosis-associated hyperglycaemia and effects on treatment outcomes in n](https://medichelpline.com/clinical-feed/plos-one-0-temporal-patterns-of-tuberculosis-associated-hyperglycaemia-and-its-effect-on.md)
- [Outer membrane vesicles and bacterial immune evasion: mechanisms and therapeutic implications](https://medichelpline.com/clinical-feed/pubmed-42742734.md) (DOI: 10.1007/s00203-026-05179-9)
- [Reconciling Genomic Ambiguity and Clinical Certainty in Refractory Panniculitis — Case Report](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-case-report-reconciling-genomic-ambiguity-with-clinical-certainty-in-refractory.md)
- [IKBKG Frameshift Variant in Pediatric Ectodermal Dysplasia With Immunodeficiency: Case Report and](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-pediatric-ectodermal-dysplasia-with-immunodeficiency-caused-by-a-hemizygous.md)
- [Impact of a Person-Centered Care Intervention on HIV Treatment Reengagement in Zambia](https://medichelpline.com/clinical-feed/plos-medicine-2-effect-of-a-person-centered-care-intervention-on-return-and-sustained.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.